Advanced Or Metastatic Solid Tumors Archives | MSD Oncology Clinical Trials

A Study to Evaluate the Bioavailability of Pembrolizumab Via Subcutaneous Injection of MK-3475A In Advanced Solid Tumors

June 5, 2023

This is a study to assess the pharmacokinetics, safety, and tolerability of pembrolizumab formulated with MK-5180 when administered as a SC injection to participants with advanced solid tumors. Participants will receive

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Tumors

March 30, 2023

By Tyler Kalist

The purpose of this study is to assess the efficacy and safety and establish a preliminary recommended Phase 2 dose (RP2D) of MK-6598 administered as monotherapy and in combination with pembrolizumab

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab In Advanced or Metastatic Solid Tumors

July 19, 2022

By Tyler Kalist

The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with

Condition: Advanced Or Metastatic Solid Tumors

Condition: Advanced Or Metastatic Solid Tumors

A Study to Evaluate the Bioavailability of Pembrolizumab Via Subcutaneous Injection of MK-3475A In Advanced Solid Tumors

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Tumors

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab In Advanced or Metastatic Solid Tumors